The administration of a humanized anti-TLR2 mAb, tomaralimab, in human tumor xenograft models of gastric and pancreatic cancers markedly inhibited the growth of tumors exhibiting high TLR2 expression and/or activation. This evidence concerns the gene TLR2 and familial pancreatic carcinoma.